65. AR/enhancer alterations in metastatic castrate-resistant prostate cancer patient plasma predicts worse overall survival

Androgen-receptor signaling inhibitors (ARSI) such abiraterone and enzalutamide have significantly improved clinical outcomes in patients with metastatic castrate-resistant prostate cancer (mCRPC). However, patients with genomic alterations in androgen receptor (AR) and its enhancer region do not respond well and acquire resistance to these inhibitors. We previously developed a cell-free DNA (cfDNA) liquid biopsy assay (EnhanceAR-Seq) that can detect alterations in AR locus including the upstream enhancer.

Source: Cancer Genetics and Cytogenetics - November 1, 2022 Category: Genetics & Stem Cells Authors: Pradeep Chauhan, Alexander Shiang, Ha Dang, Jace Webster, Elisa Ledet, Ramandeep Babbra, Wenjia Feng, Peter Harris, Faridi Qaium, Ellen Jaeger, Patrick Miller, Sydney Caputo, Giordano Santos, Russell Pachynski, A. Oliver Sartor, Christopher Maher, Aadel C Source Type: research